Clinical trial
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable Esophageal Squamous Cell Carcinoma，A Prospective, Single-Center, Open Label，Phase II Cohort Study （WATCHER）
NCT05507411 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable Esophageal Squamous Cell Carcinoma，A Prospective, Single-Center, Open Label，Phase II Cohort Study （WATCHER）
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 3, 2022
- Completion date
- April 30, 2027
- Enrollment
- 100 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.